37 patents
Utility
Formulations of Viloxazine
30 Nov 23
Modified release formulations of viloxazine and methods of administering the same are disclosed.
Michael L. Vieira, Austin B. Huang, Padmanabh P. Bhatt
Filed: 10 Aug 23
Utility
Method of Treatment of CNS Disorders
9 Nov 23
The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity
Christopher D. Breder
Filed: 17 Jul 23
Utility
Process of Making Derivatives of Substituted Morpholines
9 Nov 23
Yanjun Sun, Bhaskara Rao Nallaganchu, Gary L. Olson
Filed: 7 Jun 23
Utility
Process of Making Derivatives of Substituted Morpholines
21 Sep 23
Yanjun Sun, Bhaskara Rao Nallaganchu, Gary L. Olson
Filed: 17 Mar 23
Utility
Osmotic Drug Delivery System
17 Aug 23
An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
Argaw Kidane, Padmanabh P Bhatt
Filed: 21 Nov 22
Utility
Formulations of Mazindol
6 Jul 23
Formulations of mazindol having superior stability and methods of administering same are provided.
Argaw Kidane, Padmanabh P. Bhatt
Filed: 9 Aug 22
Utility
Method of treatment of aggression
2 May 23
The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
Christopher D. Breder
Filed: 4 Jan 19
Utility
Derivatives of substituted morpholines and uses thereof
25 Apr 23
Janak Khimchand Padia
Filed: 25 May 22
Utility
Method of Treatment of Attention Deficit/hyperactivity Disorder (Adhd)
30 Mar 23
The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
Christopher D. BREDER
Filed: 26 Aug 22
Utility
Use of Higher Doses of Modified Release Huperzine Formulations
23 Mar 23
The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine.
Stephen D. COLLINS, Peter J. GOLDSTEIN, Joshua T. JOHNSTONE
Filed: 3 Jun 22
Utility
Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
16 Mar 23
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed.
Padmanabh P. BHATT, Argaw KIDANE, Kevin EDWARDS
Filed: 15 Nov 22
Utility
Method of treatment of attention deficit/hyperactivity disorder (ADHD)
4 Oct 22
The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
Christopher D. Breder
Filed: 12 Apr 22
Utility
Derivatives of Substituted Morpholines and Uses Thereof
29 Sep 22
Janak Khimchand Padia
Filed: 18 Mar 22
Utility
Derivatives of Substituted Morpholines and Uses Thereof
22 Sep 22
Janak Khimchand Padia
Filed: 25 May 22
Utility
Method of Treatment of Attention Deficit/hyperactivity Disorder (Adhd)
28 Jul 22
The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
Christopher D. BREDER
Filed: 12 Apr 22
Utility
Use of higher doses of modified release huperzine formulations
7 Jun 22
The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine.
Stephen D. Collins, Peter J. Goldstein, Joshua T. Johnstone
Filed: 19 Nov 19
Utility
Method of treatment of attention deficit/hyperactivity disorder (ADHD)
10 May 22
The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
Christopher D. Breder
Filed: 6 Jun 17
Utility
Methods for Producing Viloxazine Salts and Novel Polymorphs Thereof
27 Jan 22
Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof.
Likan LIANG, Padmanabh P. BHATT, David DAIN, Jean-Philippe TAQUET, Aleksandr PECHENOV, Alexei TCHESNOKOV, Reynold MARIAUX
Filed: 4 Aug 21
Utility
Methods, System, and Kit for Monitoring, Diagnosing, and Treating Impulsive Aggression
20 Jan 22
The present disclosure relates to the treatment of impulsive aggression with molindone as an add-on therapy where patients are already receiving treatment for the underlying disease or disorder, e.g. attention deficit hyperactivity disorder (ADHD), bipolar disorder, autism, Tourette's syndrome or post traumatic stress disorder (PTSD), using evidence-based impulsive aggression testing methodologies and systems.
Jennifer DUGAN STOCKS, Christopher EVANS, Seung HWANG, Susan M. DALLABRIDA
Filed: 29 Sep 21
Utility
Modified Release Pharmaceutical Compositions of Huperzine and Methods of Using the Same
18 Nov 21
The present application discloses pharmaceutical compositions for modified release of huperzine.
Stephen D. Collins, Peter Goldstein, Joshua T. Johnstone
Filed: 28 Jul 21